PMV Pharma

PMV Pharmaceuticals (PMV Pharma) is a clinical-stage precision oncology company founded in 2013 in Princeton, New Jersey. The company's platform targets p53, the most commonly mutated tumor suppressor protein in human cancer, with the goal of developing mutation-specific therapies. PMV's lead candidate, rezatapopt (PC14586), is a first-in-class small molecule designed to selectively reactivate the TP53 Y220C mutation across advanced solid tumors, currently in Phase 2 clinical trials (PYNNACLE study). The company was co-founded by renowned p53 biologist Arnold Levine, Ph.D., who discovered the p53 protein in 1979, along with David Mack, Ph.D. and Thomas Shenk, Ph.D. PMV went public on NASDAQ under the ticker PMVP.